HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ: GMAB ) with a Buy and raises the price target from $38 to $40.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.